Furthermore, CYT‐102 (Fc variant of anti‐EGFR mAbs armed UCB eNK cells) will be applied in the treatment of glioblastoma multiforme and other EGFR+ solid tumors (https://cytea.bio/). Here, EGFR is linked to glioblastoma.